Published: January 2013
|Formats||Member Price||Nonmember Price|
|Individual Download||$99 / €80||$405 / €330|
|Which format is right for me?|
Recent survey results show that the pharmaceutical companies often take an overly conservative approach to NIMPs (or Non-IMPs) due to regulatory and operational ambiguity. This can lead to unnecessary expenses and process steps, which can needlessly complicate clinical trials.
The ISPE Good Practice Guide: Harmonizing the Definition and Use of Non-Investigational Medicinal Products (NIMPs) aims to provide practical operational guidance and drive a consistent industry approach to the use of NIMPs. The Guide contains criteria for classifying NIMPs and an overview of current NIMP regulatory requirements.
This in-depth Guide will help you properly manage NIMPs by providing guidance on:
Bioreactors – Everything is Bigger in Texas
Wednesday, 31 Aug 2016 17.08
Implementation of the Lifecycle Approach to Process Validation Statistics
Monday, 29 Aug 2016 17.08
Meet 2016 – 2017 ISPE International Board of Directors
Wednesday, 24 Aug 2016 19.08